Paraskevi Farmaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Paraskevi Farmaki has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Anna Garmpi
Internal Medicine Department, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens. Greece
2 shared publicationsEleni Memi
Unit of Endocrinology, Diabetes Mellitus and Metabolism, Aretaieion
2 shared publicationsGeorgios Kyriakos
Seccion de Endocrinologia y Nutrition, Hospital General Universitario Santa Lucia, Cartagena. Spain
2 shared publicationsKonstantina Kyre
Internal Medicine Department, KAT General Hospital, Athens. Greece
2 shared publicationsSpyridon Savvanis
Department of Internal Medicine General Hospital of Athens "Elpis", Athens. Greece
2 shared publications- Afroditi Nonni
First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
1 shared publication
Latest Publications
- Open Access
- 1 July 2021
- Published by Bentham Science Publishers Ltd. in Current Cardiology Reviews
- Vol. 16 (4) , 258-265
SGLT2 Inhibitors and Cardiovascular Outcomes: Do They Differ or There is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study
A new group of hypoglycemic drugs has been used to treat diabetes type 2. This group is active sodium glucose co-transporter (SGLT2) or SGLT2 inhibitors. It has been shown that besides the treatment of diabetes, this drug class is responsible for the mildness of the cardiovascular events shown in patients with diabetes type 2. However, there is an intriguing question regarding the range of SGLT2 inhibitors and if there is a difference between them or if there is a class effect among their results. EMPA-REG OUTCOME trial and the CVD-study are used to answer this question. Additional information from the DECLARE-TIMI 58 and Dapa-HF trials is studied.
- 1 July 2021
- Published by Bentham Science Publishers Ltd. in Current Cardiology Reviews
- Vol. 16 (4) , 258-265
Open AccessSGLT2 Inhibitors and Cardiovascular Outcomes: Do They Differ or There is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study
A new group of hypoglycemic drugs has been used to treat diabetes type 2. This group is active sodium glucose co-transporter (SGLT2) or SGLT2 inhibitors. It has been shown that besides the treatment of diabetes, this drug class is responsible for the mildness of the cardiovascular events shown in patients with diabetes type 2. However, there is an intriguing question regarding the range of SGLT2 inhibitors and if there is a difference between them or if there is a class effect among their results. EMPA-REG OUTCOME trial and the CVD-study are used to answer this question. Additional information from the DECLARE-TIMI 58 and Dapa-HF trials is studied.
- Open Access
- 1 July 2021
- Published by Bentham Science Publishers Ltd. in Current Cardiology Reviews
- Vol. 16 (4) , 253-257
Cardiovascular and Renal Outcomes of Incretin-based Therapies: A Review of Recent Clinical Trials
Background: To report the cardiovascular and renal effects of incretin-based therapies. Method: The studies of clinical trials on incretin-based therapy published in medical journals from the years 2010 to 2017 were comprehensively searched using MEDLINE and EMBASE with no language restriction. The studies were reviewed and the cardiovascular and renal risks reported were recorded. Results: Incretin-based therapeutics represent novel and promising anti-diabetes drugs, the direct cardiovascular actions which may translate into demonstrable clinical benefits on cardiovascular outcomes. Furthermore, incretin-based therapies do not adversely affect renal function.
- 1 July 2021
- Published by Bentham Science Publishers Ltd. in Current Cardiology Reviews
- Vol. 16 (4) , 253-257
Open AccessCardiovascular and Renal Outcomes of Incretin-based Therapies: A Review of Recent Clinical Trials
Background: To report the cardiovascular and renal effects of incretin-based therapies. Method: The studies of clinical trials on incretin-based therapy published in medical journals from the years 2010 to 2017 were comprehensively searched using MEDLINE and EMBASE with no language restriction. The studies were reviewed and the cardiovascular and renal risks reported were recorded. Results: Incretin-based therapeutics represent novel and promising anti-diabetes drugs, the direct cardiovascular actions which may translate into demonstrable clinical benefits on cardiovascular outcomes. Furthermore, incretin-based therapies do not adversely affect renal function.
- Open Access
- 22 March 2021
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 11 (3) , 223
Histone Deacetylase Inhibitors in the Treatment of Hepatocellular Carcinoma: Current Evidence and Future Opportunities
Hepatocellular carcinoma (HCC) remains a major health problem worldwide with a continuous increasing prevalence. Despite the introduction of targeted therapies like the multi-kinase inhibitor sorafenib, treatment outcomes are not encouraging. The prognosis of advanced HCC is still dismal, underlying the need for novel effective treatments. Apart from the various risk factors that predispose to the development of HCC, epigenetic factors also play a functional role in tumor genesis. Histone deacetylases (HDACs) are enzymes that remove acetyl groups from histone lysine residues of proteins, such as the core nucleosome histones, in this way not permitting DNA to loosen from the histone octamer and consequently preventing its transcription. Considering that HDAC activity is reported to be up-regulated in HCC, treatment strategies with HDAC inhibitors (HDACIs) showed some promising results. This review focuses on the use of HDACIs as novel anticancer agents and explains the mechanisms of their therapeutic effects in HCC.
- 22 March 2021
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 11 (3) , 223
Open AccessHistone Deacetylase Inhibitors in the Treatment of Hepatocellular Carcinoma: Current Evidence and Future Opportunities
Hepatocellular carcinoma (HCC) remains a major health problem worldwide with a continuous increasing prevalence. Despite the introduction of targeted therapies like the multi-kinase inhibitor sorafenib, treatment outcomes are not encouraging. The prognosis of advanced HCC is still dismal, underlying the need for novel effective treatments. Apart from the various risk factors that predispose to the development of HCC, epigenetic factors also play a functional role in tumor genesis. Histone deacetylases (HDACs) are enzymes that remove acetyl groups from histone lysine residues of proteins, such as the core nucleosome histones, in this way not permitting DNA to loosen from the histone octamer and consequently preventing its transcription. Considering that HDAC activity is reported to be up-regulated in HCC, treatment strategies with HDAC inhibitors (HDACIs) showed some promising results. This review focuses on the use of HDACIs as novel anticancer agents and explains the mechanisms of their therapeutic effects in HCC.